“
TL;DR
This preclinical mouse study developed a method to deplete CD103+ resident memory T cells (TRM) from the oral mucosa.
The Journal of Experimental Medicine · 15 authors, 5 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This preclinical mouse study developed a method to deplete CD103+ resident memory T cells (TRM) from the oral mucosa.
This preclinical study characterized CD103+ resident memory T cells (TRM) in the mouse oral mucosa. Depletion of CD103+ TRM markedly reduced proinflammatory gene signatures upon antigen re-exposure, providing proof-of-principle that TRM-depleting agents could mitigate T cell-driven non-lymphoid tissue inflammation. Conversely, reactivation of oral TRM induced regional upregulation of antitumor and metal-scavenging genes and mobilized circulating memory T cells into inflammatory aggregates. The study provides a toolbox for studying oral mucosal immunity, with limitations including the use of mouse models and the focus on basic mechanisms rather than direct clinical application.